Md. Rafiqul Islam Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Md. Rafiqul Islam Khan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anamul Haque
Department of Pharmacy , Faculty of Science , University of Rajshahi , Rajshahi , Bangladesh , ru.ac.bd
1 shared publication Anwar Habib
Department of Pharmacology, Rajshahi Medical College, Rajshahi, Bangladesh
1 shared publication- Chandan Barai
Department of Biochemistry and Molecular Biology , Faculty of Science , University of Rajshahi , Rajshahi , Bangladesh , ru.ac.bd
1 shared publication - Md. Abdul Alim Al-Bari
Department of Pharmacy , Faculty of Science , University of Rajshahi , Rajshahi , Bangladesh , ru.ac.bd
1 shared publication - Md. Jonaid Tawfiq
Department of Pharmacy , Faculty of Science , University of Rajshahi , Rajshahi , Bangladesh , ru.ac.bd
1 shared publication Milon Kumar Ghosh
Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 5624539
Mechanistic Evaluation of LolA and β ‐Sliding Clamp Inhibition by Silybin and Diclofenac as Gentamicin Adjuvants Against Enteropathogenic Escherichia coli
To address the challenges of antimicrobial resistance, one potential approach is to repurpose existing drugs. In the current study, structurally distinct antibiotics were combined with the repurposed drugs silybin and diclofenac to evaluate the potential of these combinations against resistant bacterial strains. The investigation encompassed in vitro determination of the minimum inhibitory concentration (MIC) and time‐kill kinetics, as well as in vivo assessments of percentage change in body weight, total white blood cell (WBC) count, colitis and edema, histopathological changes, stool scores, and blood culture in an enteropathogenic Escherichia coli (EPEC)‐infected mouse model. Both silybin and diclofenac potentiated the activity of several antibiotics, with gentamicin showing the most promising results. The gentamicin–silybin (Gen + Sily) and gentamicin–diclofenac (Gen + Dic) combinations not only demonstrated sustained antibacterial activity in the time‐kill assay compared with gentamicin monotherapy but also provided greater protection against crypt cell damage and more effectively alleviated colitis and edema in the EPEC‐infected mouse model. In silico molecular docking and 250‐ns molecular dynamics simulations hypothesized two potential targets implicated in antibiotic adjuvant activity: LolA and the β ‐sliding clamp protein. Molecular docking and MM/PBSA analyses indicated that silybin and diclofenac exhibited stronger binding affinities and more favorable total binding free energies toward LolA and the β ‐sliding clamp protein, respectively, than the corresponding reference compounds.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 5624539
Open AccessMechanistic Evaluation of LolA and β ‐Sliding Clamp Inhibition by Silybin and Diclofenac as Gentamicin Adjuvants Against Enteropathogenic Escherichia coli
To address the challenges of antimicrobial resistance, one potential approach is to repurpose existing drugs. In the current study, structurally distinct antibiotics were combined with the repurposed drugs silybin and diclofenac to evaluate the potential of these combinations against resistant bacterial strains. The investigation encompassed in vitro determination of the minimum inhibitory concentration (MIC) and time‐kill kinetics, as well as in vivo assessments of percentage change in body weight, total white blood cell (WBC) count, colitis and edema, histopathological changes, stool scores, and blood culture in an enteropathogenic Escherichia coli (EPEC)‐infected mouse model. Both silybin and diclofenac potentiated the activity of several antibiotics, with gentamicin showing the most promising results. The gentamicin–silybin (Gen + Sily) and gentamicin–diclofenac (Gen + Dic) combinations not only demonstrated sustained antibacterial activity in the time‐kill assay compared with gentamicin monotherapy but also provided greater protection against crypt cell damage and more effectively alleviated colitis and edema in the EPEC‐infected mouse model. In silico molecular docking and 250‐ns molecular dynamics simulations hypothesized two potential targets implicated in antibiotic adjuvant activity: LolA and the β ‐sliding clamp protein. Molecular docking and MM/PBSA analyses indicated that silybin and diclofenac exhibited stronger binding affinities and more favorable total binding free energies toward LolA and the β ‐sliding clamp protein, respectively, than the corresponding reference compounds.
- 19 April 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (7) , 909-915
Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat
Objectives: Hyperlipidaemia is a common phenomenon in diabetes mellitus. Fenofibrate (FF) is a good candidate for the treatment of lipid abnormalities in patients with type 2 diabetes. But the bioavailability as well as therapeutic efficacy of this drug is limited to its dissolution behaviour. Here, the authors assess the therapeutic efficacy of a newly formulated solid dispersion of fenofibrate (SDF) having enhanced dissolution profiles in contrast to pure FF using fructose-induced diabetic rat model. Methods: Fructose-induced diabetic rat model was developed to assess the pharmacological efficacy of the formulated SDF, and the results were compared with the effects of conventional FF therapy. Key findings: The 14 days treatment showed better improvement in lipid-lowering potency of SDF than pure FF. SDF containing one-third dose of pure FF showed similar effect in terms of triglyceride, total cholesterol and low-density lipoprotein lowering efficacy, whereas increased high-density lipoprotein at same extent. The similar dose of SDF produced more prominent effect than FF. Histological studies also demonstrated the enhanced lipid clearance from liver by SDF than FF that was concordant with the biochemical results. Conclusions: This newly formulated SDF would be a promising alternative for conventional fenofibrate in treating hyperlipidaemia.
- 19 April 2020
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (7) , 909-915
Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat
Objectives: Hyperlipidaemia is a common phenomenon in diabetes mellitus. Fenofibrate (FF) is a good candidate for the treatment of lipid abnormalities in patients with type 2 diabetes. But the bioavailability as well as therapeutic efficacy of this drug is limited to its dissolution behaviour. Here, the authors assess the therapeutic efficacy of a newly formulated solid dispersion of fenofibrate (SDF) having enhanced dissolution profiles in contrast to pure FF using fructose-induced diabetic rat model. Methods: Fructose-induced diabetic rat model was developed to assess the pharmacological efficacy of the formulated SDF, and the results were compared with the effects of conventional FF therapy. Key findings: The 14 days treatment showed better improvement in lipid-lowering potency of SDF than pure FF. SDF containing one-third dose of pure FF showed similar effect in terms of triglyceride, total cholesterol and low-density lipoprotein lowering efficacy, whereas increased high-density lipoprotein at same extent. The similar dose of SDF produced more prominent effect than FF. Histological studies also demonstrated the enhanced lipid clearance from liver by SDF than FF that was concordant with the biochemical results. Conclusions: This newly formulated SDF would be a promising alternative for conventional fenofibrate in treating hyperlipidaemia.